Kenvue (KVUE) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Net sales for the quarter ended June 28, 2026, increased 3.0% year-over-year to $4.0 billion, with organic sales up 1.6%, marking the third consecutive quarter of growth across all segments and regions.
Net income rose 8.6% to $456 million, and diluted EPS was $0.24, up from $0.22 in the prior year quarter; adjusted diluted EPS rose 7% to $0.31.
The company is undergoing a pending merger with Kimberly-Clark, expected to close in Q4 2026, with shareholders to receive a mix of stock and cash.
Transformation and restructuring initiatives are underway, including a $250 million program to optimize operations and supply chain, targeting $200 million in annualized cost savings.
Results met or exceeded internal plans, reflecting operational efficiencies and increased strategic investment.
Financial highlights
Gross profit margin declined 70 bps to 58.2% due to input cost inflation, tariffs, and FX, partially offset by supply chain optimization; adjusted gross profit margin was 60.2%.
Operating income for the quarter was $699 million, up 1.0% year-over-year; operating margin was 17.7%.
Net cash from operating activities for the six months was $1.18 billion, up 12.2% year-over-year; free cash flow for the first half was $1.0 billion.
Total debt as of June 28, 2026, was $8.5 billion; cash and equivalents were $1.1 billion.
Quarterly dividend increased 1.2% to $0.21 per share, with $796 million paid in dividends in the first half.
Outlook and guidance
The merger with Kimberly-Clark is expected to close in Q4 2026, subject to regulatory approvals.
The 2026 restructuring is expected to deliver $200 million in annualized pre-tax cost savings.
Management expects continued variability in the macroeconomic environment due to geopolitical and trade uncertainties.
Latest events from Kenvue
- Q1 2025 net sales fell 3.9% and adjusted EPS was flat, pressured by tariffs and FX.KVUE
Q1 20259 Jul 2026 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2026.KVUE
M&A Announcement8 Jul 2026 - All director nominees, executive pay, and auditor ratification were approved by shareholders.KVUE
AGM 202621 May 2026 - Net income jumped 47% on higher sales and margins, with restructuring and a major merger pending.KVUE
Q1 20267 May 2026 - Shareholders will vote on a merger, director elections, executive pay, and auditor ratification.KVUE
Proxy filing8 Apr 2026 - Proxy statement solicits shareholder votes for annual meeting with no filing fee required.KVUE
Proxy filing8 Apr 2026 - Q4 sales and margins improved, but full year sales declined; Kimberly-Clark deal pending.KVUE
Q4 202517 Feb 2026 - Merger and compensation proposals were approved by stockholders, with final results pending SEC filing.KVUE
AGM 20263 Feb 2026 - Q2 saw 1.5% organic growth, margin expansion, and a $488M impairment hit net income.KVUE
Q2 20242 Feb 2026